You are here: Industry Insights > Zanubrutinib

News List

China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.
BeiGene's Zanubrutinib to Be Approved in China CPhI.CN
May 26, 2020
Zanubrutinib is one of the world's best-selling BTK inhibitor, with sales in 2019 reached 8.08 billion USD.
MEI Pharma Announces Expansion of Zandelisib Phase 1b Study americanpharmaceuticalreview
January 11, 2021
MEI Pharma announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®) ...
BeiGene gains FDA breakthrough therapy status for zanubrutinib in mantle cell lymphoma firstwordpharma
January 16, 2019
BeiGene announced that it received a breakthrough therapy designation for its investigational Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib to treat adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.
BeiGene gains FDA breakthrough therapy status for zanubrutinib in mantle cell lymphoma firstwordpharma
January 16, 2019
BeiGene announced that it received a breakthrough therapy designation for its investigational Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib to treat adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.
BeiGene Receives FDA Breakthrough Therapy Designation for Zanubrutinib americanpharmaceuticalreview
January 16, 2019
BeiGene announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor....
MEI Pharma, BeiGene to co-develop cancer drug biospectrum
October 15, 2018
Under the terms of the clinical collaboration agreement, MEI will amend its ongoing Phase 1b trial to include evaluation of ME-401 in combination with zanubrutinib in patients with B-cell malignancies
BeiGene Announces Acceptance of its First NDA for Zanubrutinib biospectrumasia
August 30, 2018
Zanubrutinib is being studied in several clinical trials as part of a broad development program and was recently granted Fast Track Designation by the US FDA